吉非替尼 T1181

Product Introduction
Bioactivity


英文名: Gefitinib

描述: Gefitinib (ZD1839) 是一种 EGFR 一代抑制剂，具有口服活性，抑制 EGFR 19 Del 和 L858R 突变。Gefitinib 具有抗肿瘤活性，用于治疗 EGFR 突变的非小细胞肺癌。Gefitinib 用药会产生 EGFR C797S 耐药突变。

细胞实验: The human NSCLC H1299, H1975, A549, H460, GLC82, H460, and CALU-3 cell lines were provided by the American Type Culture Collection and maintained in RPMI-1640 supplemented with 10% FBS in a humidified atmosphere with 5% CO2. CALU-3 GEF-R is a cell line obtained in vitro as previously described. Briefly, over a period of 12 months, human CALU-3 lung adenocarcinoma cells were continuously exposed to increasing concentrations of gefitinib. The starting dose was the dose causing the inhibition of 50% of cancer cell growth (IC50; gefitinib, 1 μmol/L). The drug dose was progressively increased to 15 μmol/L in approximately 2 months, to 20 μmol/L after other 2 months, to 25 μmol/L after additional 2 months, and, finally, to 30 μmol/L for a total of 12 months. The established resistant cancer cell lines were then maintained in continuous culture with the maximally achieved dose of each TKI that allowed cellular proliferation (30 μmol/L for each drug) [2].

动物实验: Four- to 6-week old female balb/c athymic (nu+/nu+) mice were purchased from Charles River Laboratories. Mice were acclimatized for 1 week before being injected with cancer cells and injected subcutaneously with 107 H1299 and CALU-3 GEF-R cells that had been resuspended in 200 μL of Matrigel. When established tumors of approximately 75 mm3 in diameter were detected, mice were left untreated or treated with oral administrations of metformin (200 mg/mL metformin diluted in drinking water and present throughout the experiment), gefitinib (150 mg/kg daily orally by gavage), or both for the indicated time periods. Each treatment group consisted of 10 mice. Tumor volume was measured using the formula π/6 × larger diameter × (smaller diameter)2. Tumor tissues were collected from the xenografts and analyzed by Western blotting for the expression and activation of EGFR, AMPK, mitogen-activated protein kinase (MAPK), and S6 [2].

体外活性: 方法：23 种肿瘤细胞用 Gefitinib 处理 72 h，使用 MTT 方法检测细胞活力。结果：只有 PC9 细胞系的 IC50<1 μmol/L (高度敏感)，14 个细胞系的 IC50>10 μmol/L (抗性)，其余 8 个细胞系具有 1-10 μmol/L 的 IC50 (中等敏感）。[1]方法：肿瘤细胞 HT29、KB、Du145 和 A549 用 Gefitinib (0.032-50 μM) 处理 2 h，在细胞裂解前五分钟加入 EGF (0.1 μg/mL)，使用 Western Blot 方法检测靶点蛋白表达水平。结果：Gefitinib 在所有肿瘤细胞系中产生 EGFR 自磷酸化的剂量依赖性抑制。[2]

体内活性: 方法：为检测体内抗肿瘤活性，将 Gefitinib (3.125-200 mg/kg in 0.5% polysorbate 80) 口服给药给携带肿瘤 A431、 Du145 或 A549 的 nude 小鼠，每天一次，持续七-十五天。结果：Gefitinib 剂量依赖性方式抑制 A431、 Du145 或 A549 肿瘤生长。[2]方法：为检测体内抗肿瘤活性，将 Gefitinib (40 mg/kg，每天一次) 或 Gefitinib (200 mg/kg，每五天一次) 灌胃给药给携带人肺癌肿瘤 H3255 的 athymic nude 小鼠，持续两周。结果：每周治疗显示出比每天治疗更好的抑制作用。与每日给药方案相比，每周给药方案对 p-EGFR、p-ERK 和 p-AKT 的抑制作用更强。[3]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 18.33 mg/mL (41.02 mM)
Ethanol : 4.5 mg/mL (10 mM)


关键字: EGFR tyrosine kinase | Autophagy | lung cancer | breast cancer | phosphorylation | Inhibitor | Apoptosis | inhibit | TAMs | NSCLCs | EGFR | antitumour | Epidermal growth factor receptor | HER1 | tumor metastasis | Gefitinib | ZD-1839 | ZD 1839 | ErbB-1

相关产品: PD168393 | A-935142 | Neratinib | ALK-IN-1 | Mutated EGFR-IN-2 | EGFR/CDK2-IN-3 | EGFR-IN-85 | Naquotinib | Lapatinib ditosylate monohydrate | Mutated EGFR-IN-3

相关库: FDA-Approved Kinase Inhibitor Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Anti-Cancer Active Compound Library | Tyrosine Kinase Inhibitor Library | EMA Approved Drug Library

吉非替尼 T1181信息由TargetMol中国为您提供，如您想了解更多关于吉非替尼 T1181报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途